Status:
COMPLETED
Muscle Parameters and Pathological Response in Breast Cancer Patients
Lead Sponsor:
Acıbadem Atunizade Hospital
Conditions:
Neoadjuvant Chemotherapy
Eligibility:
FEMALE
29-72 years
Brief Summary
The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Detailed Description
In patients with operable breast cancer (BC) receiving neoadjuvant chemotherapy (NAC), the pathological response rate was found to be related to body composition. The success of complete pathologic re...
Eligibility Criteria
Inclusion
- Early and locally advanced operated breast cancer patients receiving neoadjuvant chemotherapy.
Exclusion
- Patients who did not receive neoadjuvant chemotherapy, had metastatic breast cancer and whose radiological images were not available.
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 20 2023
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT06151379
Start Date
March 1 2023
End Date
October 20 2023
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AcıbademAH
Istanbul, Turkey (Türkiye), 34782